Displaying 1 - 12 items out of 15 results
Press release
… on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of …
Press release
… 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT) --Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than …
Press release
… PD-L1 inhibition overcomes T-cell suppression at the tumor; and chemotherapy causes tumor cell death and antigen … molecularly characterized via sequencing of tumor tissue DNA and/or circulating tumor DNA samples. Progression free survival and …
Press release
… services to cancer research. Her research interests span tumor biology, biomarker discovery, preclinical … Biomarker Research program, she became fascinated with circulating tumor cells (CTCs) for use as a liquid biopsy. … proud that some of the earliest work on circulating tumor DNA (ctDNA) done with AstraZeneca and Professor Andrew …
Press release
… complex malignancy. Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is … that IASLC is in the forefront in this arena.” Although tumor tissue is historically the gold standard biospecimen … biopsy approach includes a variety of methodologies for circulating analytes. From a clinical point of view, plasma …
Press release
… Barcelona— Tumor mutational burden was not significantly associated … Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data … by whole-exome sequencing of tumor and matched normal DNA. The clinical utility of TMB on outcomes was assessed …
Press release
… safety. Minimal residual disease (MRD) was assessed using circulating tumor DNA (Guardant Reveal). Mariano Provencio, MD, PhD, Hospital …
Press release
… predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of … and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor …
Press release
… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …